Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. - Wikidata - awgldk - TriplyDB

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

http://www.wikidata.org/entity/Q34600820

about

Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation Mesenchymal stem cells and immunomodulation: current status and future prospects The current landscape of the mesenchymal stromal cell secretome: A new paradigm for cell-free regeneration Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis.Are nestin-positive mesenchymal stromal cells a better source of cells for CNS repair?Mesenchymal stem cells in multiple sclerosis - translation to clinical trials Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.Mesenchymal stem/stromal cells-a key mediator for regeneration after perinatal morbidity?A studentized permutation test for three-arm trials in the 'gold standard' design.Autologous mesenchymal stem cells applied on the pressure ulcers had produced a surprising outcome in a severe case of neuromyelitis optica Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications.Cell Therapy for Multiple Sclerosis.Multiple Sclerosis: Immunopathology and Treatment Update.Mesenchymal stem cell-derived factors: Immuno-modulatory effects and therapeutic potential.Stem Cells Therapy in Multiple Sclerosis - A New Hope for Progressive Forms.Optical coherence tomography findings in Huntington's disease: a potential biomarker of disease progression.Mammalian MSC from selected species: Features and applications.Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.Advances in mesenchymal stromal cell therapy in the management of Crohn's disease.Cell-based therapeutic strategies for multiple sclerosis.Stem cell therapy in multiple sclerosis: a future perspective.Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study.Yin and Yang of mesenchymal stem cells and aplastic anemia.Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant.Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the Treatment of Immune-Related Diseases: A Systematic Review

P2860

Q26741252-23DD4058-54BE-44BD-B637-FCBD881F1386 Q26770191-76F46940-F2D3-4501-BF97-7E1A835A6197 Q26775288-6BD1EDD9-48BF-44E0-BA8E-E2DD946BF083 Q26799013-84EDC9B4-7DA3-4C53-ABEA-BB88A538811C Q26799107-70B656F5-1BDC-4CD4-8D4B-42CFB8977583 Q30690412-B415AA60-D250-4313-A258-A9913A5A546C Q33757255-61CA08D0-DE01-472A-9692-64A83B4EDDD9 Q35422678-80B3FFE5-6856-4DAC-BC3A-9E8285F327B0 Q35722755-129DFB15-218E-472A-A136-9386C521371C Q35921652-6AF104FB-969D-41D1-BA6A-668127C85D48 Q36196674-E5D8DF7A-D25C-44AE-9DA3-3D4F03046E59 Q36443654-9BB74C02-CCAF-4A06-8D3E-3F737E3D07C9 Q37350687-FC2552EF-7C13-4D01-8561-5DDC7C88E211 Q38729214-669A10B5-4FA8-4845-87EB-0972E33C704C Q38734508-F7167D98-9956-4C11-A5DB-31C0F70B5B88 Q38837294-4EC54CCC-B6CE-40EE-A460-1ABACBD33097 Q38840236-0D2D0696-DE50-4BC0-96AC-496B377D4C69 Q39085433-AC6A5D16-9E17-421B-8B4A-A2062862A32A Q39233323-4148B197-2421-4BD9-9888-442F9F5A07DD Q39420793-4A4E297B-F692-4971-9DA1-310B0D8241E4 Q39441667-3782DDBE-73B1-484A-949F-A36E2AD7636E Q39616072-0CBB90CE-C374-4465-95F1-F2851C688371 Q45289374-8ED2D32E-C064-4161-87E8-F6A6F6809B8C Q46307085-31CC6281-426A-4AC0-B107-AEE5EC5C9E60 Q47116956-447F606B-D1CC-45FB-AFCF-BD7CD5282612 Q47287228-4C30338E-43F1-4D55-B142-7A3A09956514 Q47885870-84447F15-2F50-4630-8AFD-D80E7B174579 Q48450832-BC07056E-506D-48DE-B953-8F810A23C2E2 Q48715800-C1C76FA5-8173-4EE6-B24F-8702CA1F9C2B Q49749303-A0C91039-9E6E-48E9-925C-6352DDF68C75 Q49961729-8D211FBC-D29C-41FE-9D2A-E3154F6DBEBB Q52624498-FB5E2BE2-37A5-4284-97AE-1A1120087C14 Q54210026-74759705-639F-432E-B7C5-BE03358B6BEA Q57538743-BECD5355-A99C-47B9-8D9B-C327C993805F

P2860

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

http://www.wikidata.org/entity/Q34600820

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@ast

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@en

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@nl

type

label

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@ast

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@en

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@nl

prefLabel

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@ast

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@en

Randomized placebo-controlled ...... m cells in multiple sclerosis.

@nl

P1433

Q34600820-6CD7843A-54B9-481F-900E-1F3E3E8557E5

P1476

Q34600820-195A7BBE-7D85-40AB-8D90-8B16A716019F

P2093

Q34600820-0635B940-05AB-492F-A796-AB7A14108714

Q34600820-1A1A0986-DDCF-4837-BEEA-09B65AAAAFBA

Q34600820-2EDED0BB-103A-40E1-A6DF-335E8B4849AC

Q34600820-4C085491-40DD-4632-801A-02E9C6546F81

Q34600820-8AA3D4C0-6CC0-4041-8D13-076061375FF6

Q34600820-9B3E1B59-96C8-46F0-AADE-BBC69FB52759

Q34600820-B20F84D9-AF2A-4846-A0A9-57EF6D4D2D31

Q34600820-C9AB2A04-252F-4438-9766-A6DC2EEC860E

Q34600820-EA9B6F91-C0EB-47AC-876F-6DE5938840F0

Q34600820-EBD7DC9C-5F72-4DF7-BA93-21C106F55703

P2860

Q34600820-2AD35711-7F51-4384-8D62-8CAA236371CE

Q34600820-349B1E85-E415-49A4-8ACA-28914B8FF841

Q34600820-38FAEB30-B37D-44B8-A61B-B6F4CCD2A2E9

Q34600820-42C27B93-A805-4549-ACE1-C47D9C65594A

Q34600820-4625785A-ADA3-4D27-AC10-A2E05216DD34

Q34600820-47D0384C-34C8-4607-89D6-CCB1E5BF0304

Q34600820-4A3A009C-20B0-43EC-92F0-ACB7187609C9

Q34600820-4F8CEE9B-E5A0-45DD-82E8-240252D5A83B

Q34600820-5B49B9F6-561B-4018-832D-1AD316BB12AD

Q34600820-8F3F63C3-1A5F-4A97-B5C7-58DE1F170FF6

P304

Q34600820-C23C0257-18F2-419B-862E-50C2206549C8

P31

Q34600820-7D9F897E-E35E-4A1E-8F70-D287DB924504

P356

Q34600820-CA3EC91C-D0D1-40C6-AE8D-6CC403AD573C

P407

Q34600820-BF5E55B2-6413-4871-853A-095EB16491C5

P433

Q34600820-8893F9C7-1BF7-45E2-B6CA-4A8B7E34C603

P478

Q34600820-191057A1-85BB-43B1-8E87-C8B7089DDD26

P50

Q34600820-0B8D6BD8-6D26-4F93-B9D2-FEF4EDBFF470

Q34600820-1004338F-01D9-499C-ACED-6CE637C04FCE

Q34600820-124D3297-5960-4A50-A8CE-0C3161B31D0B

Q34600820-12C80F53-87F5-415E-B893-2B6F239119F3

Q34600820-2D80E2DC-DFED-4800-9305-5C1AA2F6CCE6

Q34600820-F1E3C260-B21E-4162-B97A-5E3110F3A9EC

P577

Q34600820-10C33327-04A7-421C-827E-A3239F6F3206

P5875

Q34600820-ED402AAA-49F6-4BAE-9550-44876A2E6972

P698

Q34600820-066A32F3-85C7-44F6-9947-A2261CA6C43B

P921

Q34600820-16686ABE-A521-4D8E-9629-3659A56120B5

Q34600820-4984E70F-ECAD-49DA-A2B3-4B47E4DDD06A

Q34600820-F2C9D229-8C98-4673-A886-214DFFAC5DA5

P932

Q34600820-3411EC7C-3DE9-4EC7-BE53-82E46D0A2704

P356

JOURNAL.PONE.0113936

P1433

P1476

Randomized placebo-controlled ...... em cells in multiple sclerosis

@en

P2093

Albert Saiz

http://www.w3.org/2001/XMLSchema#string

Beatriz Moreno

http://www.w3.org/2001/XMLSchema#string

Begoña Fernández

http://www.w3.org/2001/XMLSchema#string

Francesc Graus

http://www.w3.org/2001/XMLSchema#string

Joan Berenguer

http://www.w3.org/2001/XMLSchema#string

Joan-Albert Arnaiz

http://www.w3.org/2001/XMLSchema#string

María Sepúlveda

http://www.w3.org/2001/XMLSchema#string

Pablo Villoslada

http://www.w3.org/2001/XMLSchema#string

Pedro Marín

http://www.w3.org/2001/XMLSchema#string

Santi Bullich

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing

Regression towards the mean

Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.

Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.

P304

e113936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0113936

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Enrique J. Andreu

Nuria Sola-Valls

Eloy Martinez-Heras

Bernardo F. Sanchez-Dalmau

Iñigo Gabilondo

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269115920

http://www.w3.org/2001/XMLSchema#string

P698

25436769

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multiple sclerosis

P932

4250058

http://www.w3.org/2001/XMLSchema#string